Company intelligence

DMAC

DiaMedica Therapeutics Inc. · NASDAQ · Healthcare

Price$8.23-1.44% · −$0.12

Market cap443.46MEquity value

P / E-11.6Trailing ratio

Volume335.68KLatest session

Market data

DMAC price chart

TradingView

Related signals

1 min delayed

Browse public DMAC signals with their source context and measured market impact. Open any signal for its permanent analysis page.

DMACMar 30, 2026-8.03% since signal

DiaMedica to Report Q4 Earnings Amid Positive Phase 2 Study Clearance

DiaMedica Therapeutics is set to report its fourth quarter earnings on March 30, with analysts projecting a loss of 18 cents per share, aligning with last year's results. Additionally, the recent Health Canada clearance for a Phase 2 study of DM199 in Preeclampsia could drive future investor interest.

View signal analysis

Research